Aug 24, 2021
|
Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
|
|
Aug 04, 2021
|
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
|
|
Jul 29, 2021
|
Vertex Reports Second-Quarter 2021 Financial Results
|
|
Jul 28, 2021
|
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
|
|
Jul 19, 2021
|
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
|
|
Jul 16, 2021
|
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
|
|
Jun 28, 2021
|
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients
|
|
Jun 25, 2021
|
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis
|
|
Jun 18, 2021
|
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
|
|
Jun 11, 2021
|
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
|
|
Jun 10, 2021
|
Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
|
|
Jun 09, 2021
|
CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
|
|
Jun 09, 2021
|
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
|
|
May 10, 2021
|
Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13
|
|
Apr 29, 2021
|
Vertex Reports First-Quarter 2021 Financial Results
|
|
Apr 28, 2021
|
Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene
|
|
Apr 26, 2021
|
Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development
|
|
Apr 22, 2021
|
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
|
|
Apr 19, 2021
|
Vertex to Announce First-Quarter 2021 Financial Results on April 29
|
|
Mar 26, 2021
|
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
|
|